Brequinar for COVID-19: real-time analysis

Download Image

Post

c19early.org

Brequinar for COVID-19

1 study with 115 patients

Serious outcome risk

Brequinar

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Brequinar studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−205%

Hospitalization (1)−205%

RCTs (1)−205%

Early (1)−205%

00.511.5+

← Brequinar
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Brequinar is an orally available, small molecule, host-acting antiviral that inhibits the host enzyme dihydroorotate dehydrogenase (DHODH) to block de novo pyrimidine biosynthesis, potentially inhibiting SARS-CoV-2 replication.


Apr 28 2021	Powers et al., NCT04575038	The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2
Apr 28 2021	205% higher hospitalization (p=0.49) and 34% worse viral clearance. RCT 115 outpatients in the USA, showing no significant differences with brequinar treatment.